NCT06603987 2025-11-19
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Enrolling by invitation
Clinical Trials
9 trialsNCT05423977 2025-09-30
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Enrolling by invitation
NCT06885424 2025-07-15
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT07053904 2025-07-08
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PharmaEssentia
Phase 1 Enrolling by invitation
NCT06992687 2025-05-28
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Enrolling by invitation
NCT06169579 2024-11-15
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1 Enrolling by invitation
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Enrolling by invitation
NCT06205082 2024-03-01
A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
LittDD Medicines Ltd
Phase 1 Enrolling by invitation
NCT02555735 2023-02-01
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
Adera Labs, LLC
Enrolling by invitation